INFO	RMA	TION DISCLOSURE	CITATION	Attorney Docket N 056291-5184	No.		Application No. 10/511,744
1 	(1	Use several sheets if neces	1007	Applicants: Anderson J.	. RYAN		
		PTO Form 1449 September 24, 200	SEP 24 S	Filing Date: October 1	8, 2004	Grou	p Art Unit: 1614
		`	TRADEU.S. PA	TENT DOCUMENTS			•
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
		· · · · · · · · · · · · · · · · · · ·					
	.l.						
			FOREIGN	PATENT DOCUMENTS			
		Document No.	Date	Country	Class	Sub-Class	Translation
	-						
	+						
		OTHER ROCL	IMPRITE (Il.	ling Analogy Title Deas I) 4! 4 D -	4- \	
	1.	Baselga "New technologie		ling Author, Title, Date, I			1 1(1)·12-21 (2000)
	2.	Bozec et al. "Enhanced tur British Journal of Cancer	mour antiangioge				
	3.	colorectal cancer and non-	small cell lung ca	nhances the activity of the runcer (NSCLC) xenograft n	nodels" AAC	CR Novembe	r 2003
	4.	ZD1839, an epidermal gro	wth factor recept	, a novel vascular-targeting or tyrosine kinase inhibitor t model" Molecular Cancer	, and potenti	ates the effec	ets of radiation in a
	5.	Williams et al. "Combinat	ion of ZD1839 ("	Iressa"), and EGFR-TKI, a	nd radiother	apy increases	s antitumour efficacy in
							<u></u>
	-			-			
	-						
	-						
•	-						
	_	-					
						· 	
Examiner	1	1	Date C	Considered		 	
							•
Examinei conformai	r: Initi nce an	al if reference considered, w d not considered. Include co	hether or not cita py of this form w	tion is in conformance with ith next communication to	n MPEP 609; applicant.	; draw line th	rough citation if not in

1-WA/2829002.1 Page 1 of 1

Attorney Docket No. Clean Ref. To: U.S. Department of Commerce Patent and Trademark Office Jul. 2 8 2005 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant: Anderson J. Ryan Applicant: Anderson Applicant: Ande			· · · · ·		OPE			· .					
Appln. No.: 10/511,744 Filing Date: October 18, 2004 Examiner's Document Number MM/YYYY (Family Name of First Inventor) 1. 5,770,599	To: U.	S. De	partment of Commerc	,		نځو		Attomey Docket No.	Client Re	f.		,	
Appln. No.: 10/511,744 Filing Date: October 18, 2004 Examiner's Document Number MM/YYYY (Family Name of First Inventor) 1. 5,770,599					JUL Z O	2000	g	056291-5184					
Appln. No.: 10/511,744 Filing Date: October 18, 2004 Examiner's Document Number MM/YYYY (Family Name of First Inventor) 1. 5,770,599	INFORMA BY APPL	ATIO	N DISCLOSURE	d's	ATEME!	NTAS	y						
Part								Appln. No.: 10/511,744					
Date: July 28, 2005 Examiner: Unassigned Group Art Unit: 1646 U.S. PATENT DOCUMENTS Examiner's Document Number MM/YYYY Beaminer's Document Number MM/YYYY Beaminer's Document Number MM/YYYY Beaminer: Unassigned Group Art Unit: 1646 Name (Family Name of First Inventor) Beaminer: Unassigned Group Art Unit: 1646 Class Sub Class Date (Class Class C			•										
U.S. PATENT DOCUMENTS Examiner's Number	Date: J	uly 28	8, 2005						Group /	Art Uni	: 16	46	
Initials* Number MM/YYYY (Family Name of First Inventor) Class Date Date (Family Name of First Inventor) Date (Family Name	U.S. PATE	NT C	OCUMENTS							······			
Initials* Number	Examiner's		Document		Date	N	lame		Class	Sub		Filing	
1. 5,770,599	Initials*	ļ	Number				Name of First Inventor)					nate	
2. 5,616,582 04/1997 Barker 3. 5,457,105 10/1995 Barker 4. 2003-0144298 A1 07/2003 Curwen et al. 5. 2003-01466817 A1 09/2003 Davis et al. FOREIGN PATENT DQCUMENTS Document Number MM/YYYY Country Inventor/Applicant Name Page Including In this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 9. 01/32651 A1 05/2001 WO Davis et al. 10. 01/74360 A1 10/2001 WO Curwen et al. 11. 01/74368 A1 10/2001 WO Lee et al. 12. 02/056692 A1 07/2002 WO Lee et al. 13. Baker et al., "Blockade of Vascujaf Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 52, April 2002, pp. 1974-1983 15. Bruns et al., "Antitumper Activity of the Novel Vascular Targeting Agent', Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 16. Chaptin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent', Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadlello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressal), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 5 800 Description of Examiner.		6,423,753 B1			07/200)2		Dougherty			_	(,, cpp.cp	
2. 5,457,105 10/1995 Barker 4. 2003-0144298 A1 07/2003 Curwen et al. 5. 2003-0166617 A1 09/2003 Davis et al. FOREIGN PATENT DOCUMENTS Dockment Number Date Number Number Number Date Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Number Num		1.	5,770,599		06/199	8							/ -
4. 2003-0144298 A1 07/2003 Curven et al. 5. 2003-0166617 A1 09/2003 Davis et al. FOREIGN PATENT DOCUMENTS Document Number MM/YYYY Country Inventor/Applicant Name Abstract MM/YYYY Country Inventor/Applicant Name 6. 96/33980 031/1996 WO Gibson (equivalent to US 6,770,599) 7. 99/02166 01/1999 WO Dougherty (equivalent to US 6,423,753) 8. 00/48591 08/2000 WO Zavis et al. 9. 01/32651 A1 05/2001 WO Hennequin et al. 10. 01/74360 A1 10/2001 WO Curven et al. 11. 01/74368 A1 10/2001 WO Lee et al. OTHER (Including in this order Author, Title, Periodicar Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascudar Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for The(apy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al., "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a-nudy-mouse model", European Journal of Cancer, vol. 38, Suppl. November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 509. Powelling the proper Examiner		2.	. 5,616,582 04/19			97	Barker						
S. 2003-0166617 A1 09/2003 Davis et al.		3	5,457,105		10/199	95		Barker					
FOREIGN PATENT DOCUMENTS Document Number Date Number		4.	2003-0144298 A	1	07/200)3		Curwen et al.					
Document Number MM/YYYY Country Inventor/Applicant Name Abstract Readily Available MM/YYYY Country Inventor/Applicant Name MM/YYYY Country Inventor/Applicant Name Enclosed No		5.	2003-0166617 A	1	09/200	<u> </u>		Davis et al.					
Decement Number Date Dat	FOREIGN	PAT	ENT DOCUMENTS									Translat	ion
6. 96/33980 031/1996 WO Gibson (equivalent to US 6,770,599) 7. 99/02166 0X1999 WO Dougherty (equivalent to US 6,423,753) 8. 00/48591 08/2000 WO Pavis et al. 9. 01/32651 A1 05/2001 WO Hennequin et al. 10. 01/74360 A1 10/2001 WO Curwen et al. 11. 01/74368 A1 10/2001 WO Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in anude mouse model", European Journal of Cancer, vol. 38, Suppl. X November 2; p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner EXAMINER: Initial if citation considered, whether or not citation is in conformance with MEEP 6.600. Destribution is in conformance with MEEP 6.600. Destribution is in conformance with MEEP 6.600. Destribution in the citation considered.	2				1			Inventor/Applicant Name		Abstract	bstract		е
7. 99/02166 0N1999 WO Dougherty (aquivalent to US 6,423,753) 8. 00/48591 08/2000 WO Davis et al. 9. 01/32651 A1 05/2001 WO Hennequin et al. 10. 01/74360 A1 10/2001 WO Curwen et al. 11. 01/74368 A1 10/2001 WO Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primally pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in anuderhouse model", European Journal of Cancer, vol. 38, Suppl. November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MEE 8 609. Described in the control to the co										Enclosed	No	Enclosed	No
8. 00/48591 08/2000 WO Pavis et al. 9. 01/32651 A1 05/2001 WO Hennequin et al. 10. 01/74360 A1 10/2001 WO Curwen et al. 11. 01/74368 A1 10/2001 WO Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in anuder mouse model", European Journal of Cancer, vol. 38, Suppl. T. November 2, p. 40 16. Craplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 8 500, Drow line than the station of the considered in th		6.	96/33980	<u> </u>	1/1996	V	vo	Gibson (equivalent to US 6,77	0,599)				1
9. 01/32651 A1 05/2001 WO Hennequin et al. 10. 01/74360 A1 10/2001 WO Curven et al. 11. 01/74368 A1 10/2001 WO Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nuder mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPER 6 600 Draw line that is the second of the citation considered whether or not citation is in conformance with MPER 6 600 Draw line that is the conformance with MPER 6 600 Draw line that is the line of the provider of the provider with MPER 6 600 Draw line that is the line of the provider with MPER 6 600 Draw line that is the line of the provider with MPER 6 600 Draw line that is the line of the provider with MPER 6 600 Draw line that is the line of the provider with MPER 6 600 Draw line that is the line of the provider with MPER 6 600 Draw line that line is the line of the prov		7.	99/02166 01/1999 W		vo .	Dougherty (equivalent to US 6,4	23,753)				Т		
10. 01/74360 A1 10/2001 WO Curwen et al. 11. 01/74368 A1 10/2001 WO Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a-nude mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPES 5.00. Date in the lattice of the part of the p		+	00/48591	0	8/2000	<u> </u>	<u>0v</u>	Øavis et al.					T
11. 01/74368 A1 10/2001 WQ Davis et al. 12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in an anude mouse model", European Journal of Cancer, vol. 38, Suppl. November 2; p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 500. Drawling though status if		9.	01/32651 A1	0	5/2001	W	<u>۰ ۵۷</u>	Hennequin et al.	1				T
12. 02/056692 A1 07/2002 WO Lee et al. OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumar Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nuder mouse model", European Journal of Cancer, vol. 38, Suppl. November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPER 6 500, Draw line thereof a lating is in conformance with MPER 6 500, Draw line the unit of the lating is in conformance with MPER 6 500, Draw line the unit of the lating is in conformance with MPER 6 500, Draw line the unit of the lating is in conformance with MPER 6 500, Draw line the unit of the		10. 01/74360 A1 10/2001		N	VO	Curwen et al.					\top		
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) 13. Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nuder mouse model", European Journal of Cancer, vol. 38, Suppl. November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance with MPEP 6 600, Draw line the unit is in conformance wit		11.	01/74368 A1	10	0/2001	N	yd.	Davis et al.					1
Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nuder mouse model", European Journal of Cancer, vol. 38, Suppl. X November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance.		12.	02/056692 A1	0	7/2002	٧	vo 🔀	Lee et al.			1 -		十
Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003 14. Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nuder mouse model", European Journal of Cancer, vol. 38, Suppl. X November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance with MPEP 5 600. Draw line through citation is in conformance.	OTHER (I	ncludi	ing in this order Auth	nor,	Title, Pe	riodio	al Na	me, Date, Pertinent Pages, etc.)			T		†
Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983 15. Bruns et al, "Vascular-targeting activity of ZD6126 against primally pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in conformance with MPER 5 609. Draw line through either in con			Baker et al., "Block Epidermal Growth	ade Fac	of Vasci	ular E ptor S	Endoth Signali	elial Growth Factor Receptor and	nan	. ,			
Bruns et al, "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in anude mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40 16. Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 5 609, Draw line through picture.		<u> </u>	Blakey et al., "Antity Panel of Tumor Mo	uma veels	Activity s", Clinica	of that	ne Nov ncer F	vel Vascular Targeting Agent ZD6 Research, vol. 8, 2002, pp. 1974-	1983				+
Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496 17. Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 609. Draw line through sites in Conformance with MPE		15.	Bruns et al, "Vaccu tumour growth and in a nude mouse m	lar-i iym	argeting ph node	activ meta	ity of Z astasis	ZD6126 against primary pancreat following orthotopic tumour cell	ic injection				
Human Cancer Cells by ZD-1839 (Iressa)), an Epidermal Growth Factor Receptor- selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063 Examiner Date Considered: *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 5 609. Draw line though site is in		/	Targeting Agent", li 1491-1496	nt. J	. Radiati	on O	ncolog	y Biol. Phys. vol. 54, no. 5, 2002	pp.				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 609. Draw line through site is		17.	Human Cancer Cel selective Tyrosine I	is b	y ZD-183	39 (Ire	essa))	, an Epidermal Growth Factor Re	ceptor-				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	Examiner							Date Considered:					
not in conformance and not considered. Include copy of this form with next communication to Applicant.		R:	Initial if citation consid	dere	d, whethe	rorn	ot citat	ion is in conformance with MPEP §	609). Drav	v line th	rough	citation	—— if
	not in confo	rmano	e and not considered	. Inc	lude copy	of thi	is form	with next communication to Applica	nt.				<u> </u>

Crossed out Documents previously 1-WAZ2427423.1 CONSIDED and actions/edgeld

To: U.	S Der	(modified) partment of Commerce rademark Office	JUL 2	8 2	1 00	Attorney Doci		Client Re	f.			
INFORMA	ATIO ICAN	rademark Office N DISCLOSURE NT	STATEME	N	EX COS	Applicant:	6291-5184 Anderson J. F	Ryan				
		••				Appin. No.:	10/511,744	_				
						Filing Date:	October 18, 2	2004				
Date: J	uly 28	3; 2005				Examiner:	Unassigned	Group A	Art Unit	: 16	46	
U.S. PATE	ENT C	OCUMENTS										
Examiner's Initials*		Document Number	Date MM/YY	YY	Name (Famil	y Name of Fir	st Inventor)	Class	Sub Class	.	Filing Date	
		6,906,048	06/20	05		Davis	et al				(if appropa	riate)
			00/20			Davis	Ct di.		 -			
									 	• /		
FOREIGN	PAN	Occument Number	Date MM/YYYY		ountry	Inventor/App	licant Name		English Abstract		Translati Readily Available	
						•			Enclosed	No	Enclosed	No
· · ·	ļ			$oxed{oxed}$				/				
	<u> </u>											L
	<u> </u>			<u> </u>		<u> </u>				<u></u>	<u></u>	L
OTHER (I		ng in this order Auth								1	<u> </u>	
	18.	Ciardiello et al., "Ar Factor Receptor Ca Endothelial Growth Cancer Cells", Clin	225 Monock Factor Anti	onal sens	Antiboo se Oligo	dy in Combina pacleotide of	ation with Vascu Human GEO C	ılar Colon				
	19.	Ciardiello et al.,"A l' Epidermal Growth l October 2001, pp. 2	Novel Appro Factor Rece	ach	in the 1	reatment of	Cancer: Targeti	ng the				<u> </u>
	20.	Davis et al., "ZD612 Destruction of Turn 7247-7253	26: A Novel or Vasculate	Vas ure"	cular-ta , Cance	rgeting Agen er Research, (t That Causes \$ 52, December 2	Selective 002, pp.				
	21.	Grosios et al., "Con and 5-Fluorouracil i Research, 20, 2000	n an Experi	mer	otherap	y with Combr ine Colon Ad	retastatin A-4 Pl enocarcinoma",	hosphate Anticancer	_		,	
		Horsman et al., "Co the Anti-Cancer Th	erapy", Adv.	.Ex	o. Med.	Biol. 2000, 4	76, pp. 311-323					
	1	Huang et al., "Modu after Epidermal Gro Research, 62, Augu	wth Factor	Rec	eptor Ir	hibition by Z(umor-induced A 01839 (Iressa)"	Ingiogenesis , Cancer				

Crossed-out downents previously considered and acknowledged

ing or a	•	grade of schools	OIP	E						
	S. De _l	•	JUL 2 B	2005	Attorney Docket No.	Client Ro	ef.			
1			E.	.4	056291-5184					
INFORMA BY APPL		N DISCLOSURE ST	TATE MEDIST	ABK	Applicant: Anderson J.	. Ryan				
					Appln. No.: 10/511,744					\neg
					Filing Date: October 18,	2004				
Date: J	uly 28	8, 2005			Examiner: Unassigned	Group	Art Unit:	16	46	
	T	OCUMENTS	<u>, </u>	· ·	•					
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Famil	y Name of First Inventor)	Class	Sub Class		Filing Date	
						******		•	(if appropr	(00)
FOREIGN	PAT	ENT DOCUMENTS					English		Translation	on
		Document Number N	Date C	Country	Inventor/Applicant Name		Abstract		Readily Available	
•				_			Enclosed	No	Enclosed	No
	ļ									
	<u> </u>			· · ·						
OTHER (I					me, Date, Pertinent Pages,					
	24.	Li et al., "Preclinical E	valuations of	Therap	ies Combining the Vascula	r Targeting				
	<u> </u>	Therapies in the Trea	itment of Kap	m Pnos osi's Sa 	phate and Conventional An arcoma", Acta Oncologica,	11cancer 41, 2002, pp.				
	25.	Raben et al., "ZD183	9, a Selective	Epider	mal Growth Factor Receptor	or Tyrosine				
·		Kinase Inhibitor, Alon	e and in Com	nbination	With Radiation and Chem	otherapy as a		ł		
		vol. 29, no. 1, Suppl 4	itegy in Non- I. February 2/	Small C	ell Lung Cancer", Seminars	s in Oncology,				
	26.				Enhance Chemotherapeu	tic Agent				F
	>	Activities in Solid Tun	nor Therapy",	Int. j. C	ancer, 99, 2002, pp. 1-6					
	27,	Siemann et al., "Enha	incement of F	Radiatio	n Therapy by the Novel Va	scular				
		2002, pp. 164-171	126", Int. J. R -	adiation	Oncology Bio. Phys., vol.	53, no. 1,				
	28.		cv of Cytotex	ic Agen	ts against Human Tumor X	enografts is			·	
	.	Markedly Enhanced b	y Coadminis	tratione	FZQ1839 (Iressa), and Inh	ibitor of EGFR				
		Tyrosine Kinase", Clir 4892	nical Cancer I	Researc	h, vol. 6, December 2000,	pp. 4885-				
	29:		st Internation	al Confe	erence on Vascular Targeth	ng: Meeting				H
	30				the Antitumor Effect of Ep	idermal				Н
	 	Growth Factor Recep	tor-blocking A	Antibodi	es in Vivo: A Role for Altere	ed Tumor		<u> </u>		
		Angiogenesis", Cance	er Research,	61, July						Ы
Examiner	:D:	Initial if start · ·			Date Considered:					\Box
*EXAMINE not in confo		initial if citation consider ce and not considered. In	ed, whether or Iclude conv of	r not cita this form	tion is in conformance with Min with next communication to A	PEP § 609. Dra	w line thro	ugh	citation it	f,
				4113 10111	The rest communication to /	applicant.				

Crossed out documents previously considered and acknowledged